Bariatric surgeon Sergey Terushkin covers the heart, kidney, sleep apnea and liver approvals, plus uses like alcohol use disorder that are still being studied.
Recap by typeshit. Full story at Hackensack Meridian Health.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short teaser from a Medical Update interview on how much of the weight lost on GLP-1 drugs is muscle. The full talk is on their podcast.
Several studies at the 2026 ASCO Annual Meeting examined how GLP-1 medications and weight loss relate to breast cancer risk. These are associations, not proof of cause.
Loading…